Harvoni (ledipasvir/sofosbuvir) is a brand-name drug that’s prescribed for hepatitis C in adults and certain children. As with other drugs, Harvoni can cause side ...

Harvoni (ledipasvir/sofosbuvir) is a brand-name drug that’s prescribed for hepatitis C in adults and some children. Harvoni comes as oral tablets and pellets that ...

Gilead Sciences' Harvoni represents the first once-a-day, complete treatment pill approved by the FDA to treat the hepatitis C virus (HCV). And for some patients, the drug will be less expensive than ...

As Gilead Sciences (GILD) launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage ...

While still being on the receiving end for the high cost of sofosbuvir, Gilead's combination pill for Hepatitis C (sofosbuvir + ledipasvir) was today approved by the FDA. The FDA today approved ...

A $100 million ad blitz has whipped up patient demand for Harvoni, the $1,100-a-pill hepatitis C treatment, even as the drug’s price has drawn a barrage of lawsuits, state investigations, and sharp ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio VIENNA — Patients with genotype 4 and 5 ...

Gilead Sciences Inc. GILD announced a label expansion for its blockbuster hepatitis C virus (HCV) drug, Harvoni, for the treatment of chronic hepatitis C patients with advanced liver disease in the ...

The second subgroup evaluated 12 or 24 weeks of Harvoni plus RBV among 223 genotype 1 and 4 patients who developed HCV recurrence following liver transplantation. Among non-cirrhotic patients, SVR12 ...

The FDA has approved changes to the warnings and precautions labels for Harvoni and Sovaldi, indicating that amiodarone should not be used while taking the combination regimen of Harvoni or while ...

Gilead’s next generation hepatitis C pill Harvoni is set to be backed by NICE – and this time NHS England won’t be delaying its funding as it has done with the firm’s other hep C drug Sovaldi. In ...

Gilead Sciences consolidated its leading position in the hepatitis C virus (HCV) treatment market this week with approval for wider use of its Harvoni product in the ...